Hypothesis\nSenescent cells act as temporary architects of the extracellular matrix by secreting the ED‑A isoform of fibronectin, creating a haptotactic gradient that recruits and orients progenitor cells during tissue repair. When immune clearance fails, this gradient persists and drives maladaptive fibrosis; when senolytics remove the cells too early, the gradient disappears and regeneration stalls.\n\n## Mechanistic Rationale\nTransient senescence is enriched for a secretory program that includes ED‑A fibronectin, a splice variant known to bind integrins α5β1 and αvβ3 with high affinity (Essential role in wound healing). This matrix cue directs mesenchymal stem cells and fibroblasts to the wound edge, promoting coordinated proliferation and differentiation (Senescence contributes to regeneration). In young tissue, NK‑ and T‑cell mediated clearance removes senescent cells once the gradient has fulfilled its patterning role, preventing excess matrix deposition. In aged tissue, impaired immune surveillance (Diminished senescence response in aged wounds) lets senescent cells linger, sustaining ED‑A fibronectin deposition that fuels chronic fibroblast activation and fibrosis (Dual nature of cellular senescence). Experimental removal of senescent cells with senolytics before gradient completion abolishes the ED‑A cue, slowing wound closure unless recombinant ED‑A fibronectin is supplied (Senescent cells essential for wound healing). Thus, the senescent cell’s chaperone function is not merely signaling via soluble SASP factors but also via a matrix‑based positional information system.\n\n## Testable Predictions\n1. In murine full‑thickness excisional wounds, genetic ablation of p16^high^ senescent cells after day 3 post‑injury will preserve the ED‑A fibronectin gradient and accelerate healing, whereas ablation at day 0 will erase the gradient and delay closure.\n2. Pharmacologic senolytic treatment (navitoclax) administered at day 0 will reduce wound‑area ED‑A fibronectin immunoreactivity by >70 % and impair fibroblast alignment, an effect rescued by topical application of recombinant ED‑A fibronectin.\n3. Aged mice exhibiting delayed immune clearance will show prolonged ED‑A fibronectin deposition correlating with increased collagen I crosslinking and reduced progenitor cell recruitment; boosting NK‑cell activity (IL‑15 superagonist) will restore timely clearance and normalize gradient dynamics.\n\n## Experimental Design\n- Use p16‑3MR mice to inducibly senescent‑cell‑clear via ganciclovir at defined times post‑wound.\n- Immunostain wound sections for ED‑A fibronectin (specific antibody) and quantify gradient intensity and spread.\n- Track progenitor cell recruitment using GFP‑labelled bone‑marrow‑derived mesenchymal stem cells.\n- Measure tensile strength and histology for fibrosis (Masson’s trichrome, hydroxyproline assay).\n- Include control groups receiving recombinant ED‑A fibronectin or vehicle.\n\nIf early senolytic clearance abolishes the ED‑A gradient and impairs repair, while later clearance or gradient rescue restores it, the hypothesis is supported; persistence of the gradient in aged wounds linked to fibrosis would further confirm the dual role of senescent cells as both regenerative architects and, when not cleared, pathogenic drivers.
